Explore more price target data and ratings for Illumina, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Illumina, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is n…
Q2 2026 saw robust revenue and EPS growth, driven by strong clinical demand, expanding NovaSeq X placements, and innovation in multi-omics and AI-enabled offerings. Full-year guidance was raised for revenue and EPS, with clinical markets and new products expected to drive future growth.Based on Ill…
Q2 2026 saw revenue rise 6.5% organically to $1.16B, with non-GAAP EPS up 10% to $1.31. Sequencing instruments led growth, while Greater China declined. FY26 guidance projects continued mid-single-digit organic growth and stable margins.Original document: Illumina, Inc. [ILMN] Slides Release — Jul…
Genomics company Illumina NASDAQ:ILMN reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company’s full-year revenue guidance of $4.62 billion at the midpoint came in 1.1% above analysts’ estimates. Its non-GAAP profit of $1.31 p…
Genomics company Illumina NASDAQ:ILMN will be announcing earnings results this Thursday after market close. Here’s what to expect.Illumina beat analysts’ revenue expectations last quarter, reporting revenues of $1.09 billion, up 4.8% year on year. It was a strong quarter for the company, with a sol…
Explore more price target data and ratings for Illumina, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Illumina, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is n…
SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026.On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Of…
While electric vehicles and tech giants like Tesla TSLA and Alphabet GOOGL dominate headlines in the robotics space, a powerful transformation has reached an inflection point in healthcare. Over the past decade, robotics in medicine has moved from early adoption to mainstream scale.This acceleratio…
(16:26 GMT) Illumina Price Target Raised to $200.00/Share From $155.00 by Evercore ISI Group
Illumina (NASDAQ:ILMN) faces fresh competitive pressure as Roche launches the $750,000 Axelios NGS system aimed at its NovaSeq X franchise, even as Guggenheim raised Illumina’s price target to $200, signaling confidence in its valuation amid the market challenge.Previous Week Recap This…
